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Abstract 
Each year the pharmaceutical industry makes thousands of compounds, many of which do not meet the 
desired efficacy or pharmacokinetic properties, describing the absorption, distribution, metabolism and 
excretion (ADME) behavior. Parameters such as lipophilicity, solubility and metabolic stability can be 
measured in high throughput in vitro assays. However, a compound needs to be synthesized in order to be 
tested. In silico models for these endpoints exist, although with varying quality. Such models can be used 
before synthesis and, together with a potency estimation, influence the decision to make a compound. In 
practice, it appears that often only one or two predicted properties are considered prior to synthesis, 
usually including a prediction of lipophilicity. While it is important to use all information when deciding 
which compound to make, it is somewhat challenging to combine multiple predictions unambiguously. This 
work investigates the possibility of combining in silico ADME predictions to define the minimum required 
potency for a specified human dose with sufficient confidence. Using a set of drug discovery compounds,
 
in 
silico predictions were utilized to compare the relative ranking based on minimum potency calculation with 
the outcomes from the selection of lead compounds. The approach was also tested on a set of marketed 
drugs and the influence of the input parameters investigated. 
Keywords 




Drug design is a multi-parameter optimization process, with pharmacokinetic properties describing 
absorption, distribution, metabolism and excretion (ADME) of a compound being important to consider 
early on. These parameters describe the pharmacokinetics of a compound and are key to determining the 
dose required for efficacy. Parameters such as lipophilicity, solubility, and metabolic stability can be 
measured in a high throughput manner in vitro and are, thus, often used as early ADME screens. During 
lead identification and lead optimization phases a substantial number of compounds is synthesized and 
characterized in such screening assays for selection towards additional, more costly in vitro and in vivo 
experiments to be able to finally select a single candidate drug. However, a compound needs to be 
physically available to be subjected to such assays. Thus, drug industry generates thousands of compounds 
per month out of which many do not show desirable ADME properties.  
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In silico models for such ADME endpoints, on the other hand, have been available for a long time, 
though with varying quality and usability [1-6]. Ideally, such models would be used before synthesis and, 
together with any potency estimation for the specific case, influence the decision to make a compound. 
Consequent usage of such in silico predictions has the potential to considerably reduce the number of 
synthesized compounds with inadequate ADME properties. In practice, it seems that most often only a few 
predicted properties are really considered before synthesis, usually including lipophilicity as important 
parameter. While it is understood that all available knowledge should be used to select which compound to 
make, it is not easy to define how the outcome of various predictions can be combined unambiguously. 
Lately, the use of multi-parameter optimization and scoring tools has been proposed and shown to be of 
value [7, 8]. However, the definition of the scoring functions can be difficult and may be a bit arbitrary. As 
physiologically meaningful scoring function the predicted dose to man (D2M) has been suggested to utilize 
as early as possible. Several reports validated early D2M predictions both from preclinical in vivo data [9] as 
well as from in vitro data combined with in silico predictions [10]. However, using in silico predictions only 
was not found to be reliable enough, since both potency and pharmacokinetic properties would need to be 
accurately predicted. 
Here we concentrate on the pharmacokinetic properties only and suggest to use in silico ADME models 
to predict what potency would be required for a specific compound to enable coverage during the whole 
dosing interval. By reverting the D2M equation and setting the target dose to, for example, 100 mg once 
daily, the achievable plasma concentration can be calculated from in silico predicted parameters and the 
minimum required potency (“threshold pIC50”) defined as ranking score for virtual compounds. We show 
how such a ranking score could be used in the discovery setting on the example of a set of 27 compounds 
leading towards a candidate structure [11]. We also test the concept on a set of known drugs with 
information about dosing and human pharmacokinetics [9] and compare the results from purely in silico 
predictions to those from in vitro data and from human in vivo data. We also investigate how the in silico 
derived parameters influence the outcome of the equations, highlighting concepts to help drug discovery to 
improve pharmacokinetic properties during design. 
Experimental  
Inverse dose-to-man (D2M) prediction 
Equations used are standard pharmacokinetic equations [9, 12, 13] based on a one compartment model 
considering immediate absorption to estimate the average (Cave, Eq. 1), minimum (Cmin, Eq. 2) and 
maximum (Cmax, Eq. 3) concentration of a drug at steady state. 
   (1)
 
   (2)
 
    
(3)
 
where F is bioavailability (Eq. 4), Dpo is the daily oral dose, Cl is the plasma clearance estimated using the 
well-stirred model (Eq. 5),  is the dosing interval, typically set to 24 h, V is the volume of distribution 
(predicted) and ke is the elimination constant (Eq. 6). 
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where Fabs (fraction absorbed) is estimated from permeability (Eq. 7), Fg (fraction escaping gut metabolism) 
is set to 1 and Fh (fraction escaping hepatic metabolism) is estimated from Cl (Eq. 8). 
   
(5)
 
with Clb being blood clearance, Qh the liver blood flow (20 ml/min/kg), CLintin vivo the in vivo intrinsic 
clearance estimated from in vitro CLint (Eq. 9), and fub the fraction unbound in blood. 
Cl =  Clb ∙ 𝑅b , (5a)  
where Rb is the blood plasma ratio and set to 1 for neutrals and bases, whereas set to 0.55 for acids and 
zwitterions. 
𝑓ub = 𝑓u/𝑅b , (5b) 
where fu is fraction unbound in plasma (predicted). 
𝑘e = Cl/𝑉            (6) 
Fabs = 1, if Papp > 1 x 10
-6 cm/s, otherwise Fabs = Papp ,        (7) 
where Papp is apparent permeability measured in Caco2 cells, utilising the intrinsic Caco2 permeability assay 
[14] (predicted). 
𝐹ℎ = 1 − 𝐶𝑙𝑏/𝑄ℎ (8) 
𝐶𝐿𝑖𝑛𝑡𝑖𝑛 𝑣𝑖𝑣𝑜 = 𝐶𝐹 ∙ 𝐶𝐿𝑖𝑛𝑡𝑠𝑐,   (9) 
where CF is an empirical correction factor adopted for the simplified regression offset approach (CF=3, see 
below), and CLintsc is the scaled intrinsic clearance from the human hepatocyte incubation (Eq. 9a). 
𝐶𝐿𝑖𝑛𝑡𝑠𝑐 = 𝐶𝐿𝑖𝑛𝑡𝐻𝐻 ∙ 𝑆𝐹𝐻𝐻/𝑓𝑢𝑖𝑛𝑐,  (9a) 
where CLintHH is the intrinsic clearance in human hepatocytes (predicted), SFHH are the scaling factors (120 
million cells per g liver x 1680 g liver weight / 70 kg body weight = 2.88) and fuinc is the fraction unbound in 
the hepatocyte incubation (predicted). 
The minimum potency value, e.g., “threshold pIC50” based on Cmin, is then calculated as the negative 
logarithm of the predicted concentration considering the specific fold coverage, typically set to 1 or 3 (Eq. 
10). 
threshold pIC50 =  −log(𝐶min fold coverage⁄ )  (10) 
Simplified regression offset approach – correction factor (CF) 
The regression offset approach [15] was shown to improve in vitro to in vivo scaling of clearance, 
especially when experiments where compared from different laboratories (sites) and using different 
batches of hepatocytes or microsomes. Extensive in-house data analysis (data not shown) indicated that 
overall the regression slope can be set to 1 and the offset to about 0.5, giving an equivalent level of correct 
predictions in three species, human, rat and dog. Thus, in vivo CLint can be estimated by multiplying the 
scaled CLint with a correction factor of 3. Here we adopt this procedure to estimate in vivo CLint directly 
from in silico predictions. 
In silico models 
Five in silico models were used as input for the above calculations. Human volume of distribution at 
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steady state, intrinsic Caco2 permeability, human plasma protein binding, human hepatocyte intrinsic 
clearance, and fraction unbound in the hepatocyte incubation. All but the volume of distribution model 
used AstraZeneca in-house experimental data. All models are available within AstraZeneca. 
1. Human volume of distribution (V) 
Human volume of distribution data for about 700 compounds were collated from literature [16-18] and 
randomly split into a training and test set (n = 544 and 144, respectively). Both acids, bases, neutral and 
zwitterionic compounds are included in both datasets. It is a random forest model [19] using physico-
chemical descriptors [20] including ACD log P and log D [21] and clog P [22]. The experimental data is 
modelled in its logarithmic form. The prediction explains ~70 % of the variance of the test set, and has an 
error in prediction of 0.4 log units. 
2. Intrinsic Caco2 permeability (Papp) 
The model is built on in-house data of intrinsic Caco2 permeability, apparent permeability measured in 
Caco2 cells in presence of a defined transport inhibitor cocktail as described earlier [14], and updated about 
every sixth month. The present training set consists of >4,000 data points. About 100 simple physico-
chemical descriptors [20] including ACD log P and log D [21] and clog P [22] are calculated from the 
compound structures. The data is modelled as log Papp using  random forest regression [19] as implemented 
in scikit-learn [23]. The latest temporal test set comprises about 300 compounds and shows an R2 of 0.4 
and a root mean squared error of predictions (RMSEP) of 0.6 (log scale), with about 60 % of the compounds 
being within 3-fold of the experimental value. The model can be used to distinguish between high and low 
permeability compounds with classification accuracy above 0.8. 
3. Human plasma protein binding as fraction unbound (fu) 
The model is built on in-house data of human plasma protein binding generated using equilibrium 
dialysis in high throughput assays as described earlier [24-26]. It is updated monthly. The present training 
set consists of almost 90,000 compounds. The data is modelled as log K (= log[(fraction unbound)/(fraction 
bound)]). The modelling procedure utilizes support vector machines [27] with a linear kernel, signature 
descriptors [28] and the conformal prediction framework [29] as implemented in cpsign from GenettaSoft 
[30]. The latest temporal test set comprising 750 compounds shows an R2 of 0.7 and an RMSEP of 0.4, with 
about 80 % of the compounds being within 3-fold of the experimental value of fu.  
4. Human hepatocyte intrinsic clearance (CLintHH) 
The model is built on in-house data of human hepatocyte intrinsic clearance generated in high 
throughput assays using incubations of either cryopreserved or fresh human hepatocytes at 37 °C for up to 
120 min as described earlier [26, 31, 32]. It is updated about every sixth month. The present training set 
contains more than 11,000 compounds and the data is modelled as log CLint. The modelling procedure 
utilizes support vector machines [27] with a linear kernel, signature descriptors [28] and  the conformal 
prediction framework [29] as implemented in cpsign from GenettaSoft [30]. The latest temporal test set 
comprising almost 200 compounds shows an R2 of 0.2 and an RMSEP of 0.4, with ~75 % of the compounds 
being within 3-fold of the experimental CLint value.  
5. Fraction unbound in the hepatocyte incubation (fuinc) 
The model is built on in-house binding data measured in cryopreserved rat hepatocyte incubations as 
described earlier [33]. The model is updated approximately every sixth month and the present data set 
contains about 1,700 compounds. The data is modelled as log K (= log[(fraction unbound)/(fraction 
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bound)]). The modelling procedure utilizes support vector machines [27] with a radial basis function kernel, 
signature descriptors [28] and the conformal prediction framework [29] as implemented in cpsign from 
GenettaSoft [30]. The latest temporal test set comprising about 200 compounds shows an R2 of 0.5 and an 
RMSEP of 0.5, with ~75 % of the compounds being within 3-fold of the experimental fuinc value. 
Global Sensitivity Analysis 
Global sensitivity analysis  was performed by a quasi-Monte Carlo method using the Fourier amplitude 
sensitivity test (FAST) and Sobol’ sensitivity, which are implemented in the Global sensitivity analysis 
toolbox (GSAT) [34] in MATLAB [35] using 20,000 sample points.  
Local Sensitivity Analysis 
 Local sensitivity analysis was performed by taking Jacobian matrices of the model with respect to the 
model parameters and other parameter points [36]. These matrices contain actual parameter values which 
can be examined, or plotted graphically against other parameters, to show which have the greatest effect 
















 ,        (11) 
 
where 𝑞 = (𝑞1, … , 𝑞𝑚) is a vector of parameter points to be examined, 𝑝 = (𝑝1, … , 𝑝𝑛)  is a vector of other 
parameters which are being examined, and x  is a scalar output from the model. This was performed in 
MATLAB [35] using automatic differentiation of the parameters via the myAD toolkit [37]. 
Data sets 
Two data sets were used for the present analysis. Data set 1 was a set of 27 drug discovery compounds 
exemplifying important compounds leading towards candidate selection [11]. Data set 2 was a set of 21 
marketed drugs, for which potency data, dosing information and human pharmacokinetic data had been 
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Results and Discussion 
Calculation of required minimum potency (threshold pIC50) for a set of drug discovery compounds 
As proof of concept a set of drug discovery molecules leading towards a candidate structure [11] was 
evaluated. Intrinsic clearance in human hepatocytes, fraction unbound in the incubation, fraction unbound 
in plasma, volume of distribution and intrinsic Caco2 permeability were predicted for all compounds using 
the present in-house models (see Table 1) and minimum and maximum plasma concentrations for a once 
daily oral dose of 100 mg calculated using equations 2 and 3. The project aimed at minimum plasma 
concentrations with 3-fold coverage over potency measured as pIC50 in a whole blood assay. Thus, 
threshold pIC50 values were calculated from Cmin,total/3 (see Table 2). Blood plasma ratios for these mainly 
neutral compounds were considered to be 1. Protein binding was considered in the scaling approach, but 
threshold pIC50s were based on resulting total plasma concentration to match the potency measurement. 
The data indicated that some of the compounds had very short half-life and thus a once daily dose 
resulted in a high threshold pIC50 to cover potency over 24 hours and a high Cmax/Cmin ratio. Using a 10 
times higher dose would reduce the threshold pIC50 by one unit, but show the same Cmax/Cmin ratio, since 
the applied model assumes linear kinetics. Considering only compounds with a threshold pIC50 below 9 and 
a Cmax/Cmin ratio below 100 about 12 compounds remained. This set of compounds included compound 15b, 
the compound finally selected, and three of the remaining four compounds of higher interest for which rat 
in vivo results were reported. Compound 22, which according to the present analysis was least favourable, 
was actually found in the rat study to have short half-life and, thus, not suitable to progress. 
In summary, it seems that for this data set the threshold pIC50 together with the predicted Cmax/Cmin 
ratio could be used for ranking the compounds and correctly identify those with inferior pharmacokinetics. 
The results also highlight the danger in deprioritizing compounds just by applying a cut-off for, for example, 
metabolic stability. Here, three compounds had (predicted) CLint values higher than 20 µl/min/106 cells, 
compounds 12, 14a and 19. For 12, a reference compound, threshold pIC50 was one of the lowest in the 
whole set based on a predicted blood clearance below 5 ml/min/kg, whereas 14a showed an intermediate 
threshold pIC50 (8.2) and blood clearance just above 5 ml/min/kg. Only for compound 19 the threshold 
pIC50 was estimated to be on the high end within the present set, even though the blood clearance was 
again predicted as just above 5 ml/min/kg. 22, the compound with the highest threshold pIC50 has almost 
double the blood clearance despite a lower hepatocyte CLint (~ 8 µl/min/106 cells). Rank order differences 
between in vitro (or in silico) CLint and predicted in vivo clearance can be explained by the different binding 
properties: High binding in the incubation, i.e., low fuinc values, will potentiate the metabolic instability 
measured in the incubation, whereas high binding in plasma, i.e., low fu, can to some extent mitigate low 
metabolic stability seen in vitro. Furthermore, minimum concentrations mainly depend on a compound’s 
half-life, determined by clearance and volume of distribution. Thus, volume of distribution is another 
important factor that again may change the rank order.  
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12 20.2 37.7 1.1 20 2.0 447.6 neutral 
13a 15.0 38.1 2.5 5 2.1 433.6 neutral 
13b 6.5 25.4 3.4 9 2.0 433.6 neutral 
14a 27.3 80.2 2.4 26 1.7 447.5 neutral 
14b 7.5 72.4 15.3 5 2.0 446.5 base 
14c 9.5 73.1 10.5 36 1.3 431.5 neutral 
14d 10.3 83.5 9.4 10 0.9 444.5 neutral 
14e 6.8 74.9 4.3 27 1.5 447.5 neutral 
15a 10.3 70.6 7.5 2 1.2 433.5 neutral 
15b 3.7 56.9 10.2 7 1.4 433.5 neutral 
15c 6.7 55.7 5.3 12 1.5 432.5 neutral 
15d 3.6 47.4 10.7 7 1.4 433.5 neutral 
15e 6.3 55.9 4.2 11 1.4 447.5 neutral 
15f 6.1 47.6 5.0 7 1.4 431.5 neutral 
19 32.3 70.9 1.8 10 0.8 416.4 neutral 
20 8.1 76.1 4.3 12 1.0 458.5 neutral 
21 12.9 76.0 2.5 13 1.2 415.5 neutral 
22 7.9 39.2 10.3 6 0.9 386.4 neutral 
29 4.7 49.8 8.0 9 1.5 447.5 neutral 
30 5.8 47.5 6.7 9 1.6 447.5 neutral 
31 4.1 47.0 9.6 10 1.5 447.5 neutral 
32 5.4 52.2 11.5 9 1.5 445.5 neutral 
37 2.6 40.6 8.8 8 1.3 469.5 neutral 
41 3.7 56.9 10.2 7 1.4 433.5 neutral 
42 4.6 46.6 7.7 8 1.7 461.6 neutral 
47 2.3 67.1 24.2 7 1.3 433.5 neutral 
49 4.0 49.0 16.9 8 1.4 421.5 neutral 
a
cmpd ID: compound identification as originally defined [11]; 
b
CLintHH: intrinsic clearance in human hepatocytes; 
c
fuinc: 
fraction unbound in rat hepatocyte incubation; 
d
fu: fraction unbound in human blood plasma; 
e
Papp: apparent permeability 
in Caco2 cells with transport inhibition; 
f
V: human volume of distribution at steady state; 
g
MW: molecular weight 
 
 
Susanne Winiwarter et al.   ADMET & DMPK 6(1) (2018) 15-33 
22  
Table 2. Predicted PK properties for compound set 1 [11] based on in silico ADME model predictions, plasma 

















14e 2.88 0.66 0.12904 1.90 7.4 14.7 
12 4.17 0.42 0.06645 1.32 7.7 19.9 
15e 3.41 0.54 0.06363 1.90 7.7 29.8 
21 3.13 0.64 0.06105 2.44 7.7 39.9 
15c 4.33 0.42 0.02902 1.73 8.0 59.5 
20 3.30 0.55 0.02517 2.56 8.1 101.6 
42 4.92 0.33 0.02259 1.38 8.1 61.0 
13b 5.45 0.31 0.02254 1.25 8.1 55.4 
37 3.96 0.43 0.02136 1.96 8.1 91.5 
15b 4.47 0.40 0.01900 1.84 8.2 96.8 
41 4.47 0.40 0.01900 1.84 8.2 96.8 
15f 4.37 0.41 0.01864 1.93 8.2 103.4 
14a 5.22 0.31 0.01757 1.39 8.2 79.2 
13a 6.03 0.26 0.01675 1.13 8.3 67.7 
29 4.88 0.34 0.01431 1.64 8.3 114.7 
30 5.27 0.31 0.01154 1.53 8.4 132.3 
31 5.36 0.30 0.00998 1.54 8.5 154.0 
15d 5.26 0.32 0.00709 1.78 8.6 250.9 
47 5.34 0.31 0.00599 1.80 8.7 300.1 
14b 8.10 0.16 0.00259 0.97 9.1 374.3 
32 6.83 0.21 0.00171 1.45 9.2 846.0 
15a 6.41 0.24 0.00074 1.91 9.6 2573.8 
49 7.51 0.20 0.00060 1.53 9.7 2537.8 
14c 7.44 0.19 0.00046 1.58 9.8 3398.1 
19 5.18 0.34 0.00045 3.01 9.8 6751.1 
14d 6.65 0.22 0.00004 2.46 10.9 58276.0 
22 9.46 0.14 0.00000 2.20 12.8 4832468.9 
a
cmpd ID: compound identification as defined in ref [11]; 
b
Cl blood: predicted human blood clearance; 
c
Cave: predicted total average 
plasma concentration at steady state; 
d
Cmin: predicted total minimum plasma concentration at steady state; 
e
Cmax: predicted total 
maximum plasma concentration at steady state; 
f
threshold pIC50 from Cmin: minimum required pIC50 estimated from Cmin/3 for a 3-
fold coverage over 24 hours; 
g
Cmax/Cmin: predicted ratio between maximum and minimum concentration at steady state 
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Calculation of threshold potency for a set of known drugs 
As second test, we investigated the approach for a set of marketed drugs where information on dosing 
and human pharmacokinetic data had been collated by McGinnity et al. [9]. This dataset was previously 
used to evaluate the validity of early dose to man predictions [9, 10]. Table 3 shows in silico ADME 
parameters for the 21 drugs predicted with the present models at AstraZeneca. 


















Acebutolol 7.7 79.0 80.8 2.5 1.5 336.4 base 
Atenolol 1.6 89.7 92.4 0.3 1.5 266.3 base 
Betaxolol 10.0 82.1 51.0 17.6 3.8 307.4 base 
Bisoprolol 9.5 82.1 63.8 12.6 2.3 325.4 base 
Carvedilol 25.0 19.5 0.6 4.8 1.9 406.5 base 
Cimetidine 5.2 77.7 81.2 4.8 1.0 252.3 base 
Cyclosporin 738.4 97.4 0.5 1.4 2.0 1203 neutral 
Desloratidine 9.2 11.9 7.8 19.4 7.8 310.8 base 
Diazepam 6.5 14.6 3.7 55.3 1.1 284.7 neutral 
Diclofenac 55.2 52.8 1.8 33.8 0.3 296.2 acid 
Famotidine 2.5 77.6 78.1 0.7 0.9 337.5 base 
Indomethacin 7.5 39.7 0.6 74.1 0.2 357.8 acid 
Irbesartan 15.1 17.7 0.8 15.6 0.9 428.5 acid 
Metoprolol 4.9 87.3 73.1 13.4 2.4 267.4 base 
Nadolol 4.4 79.8 76.9 0.4 2.1 309.4 base 
Nifedipine 14.3 30.7 3.5 45.0 1.2 346.3 neutral 
Pirenzepine 8.5 86.8 50.7 0.5 1.7 351.4 base 
Prazosin 6.5 58.8 9.9 10.1 0.8 383.4 neutral 
Propranolol 9.5 59.5 18.8 31.0 3.0 259.3 base 
Ranitidine 5.6 69.4 80.2 2.2 1.2 314.4 base 
Ritonavir 75.3 19.1 1.1 4.0 0.9 721 neutral 
a
CLintHH: intrinsic clearance in human hepatocytes; 
b
fuinc: fraction unbound in rat hepatocyte incubation; 
c
fu: fraction unbound 
in human blood plasma; 
d
Papp: apparent permeability in Caco2 cells with transport inhibition; 
e
V: human volume of distribution 
at steady state; 
f
MW: molecular weight. 
 
To take into account that these drugs are not necessarily given once daily only, we adopted the dosing 
regimen suggestion by McGinnity et al. [9] when calculating the minimum required potency, threshold pX 
(see Table 4). The resulting threshold pX values are below 10 for all but four of the compounds, thus 
indicating that the approach is able to estimate pharmacokinetic behaviour to some extent. Additionally, 
the Cmax/Cmin ratio was estimated as below 100 for most of the compounds, even though it showed values 
above 1000 for three of them (ritonavir, bisoprolol and diclofenac). The availability of both in vitro [10] and 
in vivo [9] data for the compounds prompted us to investigate, to what extent the usage of experimental 
data would change the results (see Table 5 and Figure 1). 
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Table 4. Dosing interval, predicted plasma concentrations and threshold pX based on a daily dose of 100 mg (1.4 

















Acebutolol 8 0.00165 0.00134 0.21153 8.9 127.9 
Atenolol 12 0.00742 0.00686 0.35626 8.2 48.0 
Betaxolol 12 0.01102 0.00563 0.17910 8.2 16.3 
Bisoprolol 24 0.00004 0.00002 0.44702 10.6 11795.4 
Carvedilol 8 0.19649 0.00114 0.65630 8.9 3.3 
Cimetidine 4 0.01081 0.00878 0.28422 8.1 26.3 
Cyclosporin 12 0.00155 0.00001 0.12384 11.2 79.9 
Desloratidine 24 0.01218 0.00095 0.17440 9.0 14.3 
Diazepam 12 0.00572 0.00021 1.35487 9.7 236.9 
Diclofenac 4 0.00002 0.00000 1.26227 12.4 55501.6 
Famotidine 6 0.00631 0.00493 0.42939 8.3 68.1 
Indomethacin 6 0.16284 0.00095 5.90360 9.0 36.3 
Irbesartan 8 0.01792 0.00015 0.82347 9.8 46.0 
Metoprolol 8 0.02235 0.01635 0.29316 7.8 13.1 
Nadolol 8 0.00547 0.00421 0.10158 8.4 18.6 
Nifedipine 6 0.04706 0.00164 0.54780 8.8 11.6 
Pirenzepine 12 0.00055 0.00028 0.18872 9.6 345.6 
Prazosin 6 0.04517 0.00448 0.84533 8.3 18.7 
Propranolol 8 0.05111 0.00961 0.32040 8.0 6.3 
Ranitidine 6 0.00271 0.00218 0.26131 8.7 96.3 
Ritonavir 8 0.00021 0.00000 0.26073 11.6 1239.4 
a
Dosing interval as suggested by McGinnity et al. [9], based on their predicted t1/2: t1/2>8h  24h; t1/2 4-8 h  12h; t1/2 2-4h  
8h; t1/2 1-2 h  6h; t1/2 < 1h  4h; 
b
Cmin,total: predicted minimum total concentration at steady state; 
c
Cmin,free: predicted minimum 
concentration at steady state corrected for plasma protein binding; 
d
Cmax,total: predicted maximum total concentration at steady 
state; 
e
threshold pX from Cmin,free: required minimum pX estimated from free Cmin for coverage over dosing interval; 
f
Cmax/Cmin: 
predicted ratio between maximum and minimum total concentration at steady state. 
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Table 5. Threshold pX based on a daily dose of 100 mg (1.4 mg/kg), given as 1-6 doses per 
day,  for 21 known drugs[9], derived from in silico data (as above), in vitro data [9, 10, 14], 
and actual human in vivo data [9] 
Drug name 
Threshold pX 
from in silicoa 
Threshold pX 
from in vitrob 
Threshold pX from 
in vivoc 
Acebutolol 8.9 6.9d 7.8 
Atenolol 8.2 7.8e,f 6.5 
Betaxolol 8.2 7.6e 6.4 
Bisoprolol 10.6 7.6e 6.6 
Carvedilol 8.9 9.7d 9.3 
Cimetidine 8.1 6.8d,f 7.1 
Cyclosporin 11.2 NVg 8.9 
Desloratidine 9.0 7.5d,h NVg 
Diazepam 9.7 6.9d 6.8 
Diclofenac 12.4 8.9i,j 16.0 
Famotidine 8.3 7.8d,f 7.4 
Indomethacin 9.0 9.3e,f 9.5 
Irbesartan 9.8 8.8e 8.8 
Metoprolol 7.8 6.6e 7.9 
Nadolol 8.4 7.4d,f 6.7 
Nifedipine 8.8 9.0d 8.8 
Pirenzepine 9.6 8.0e 7.2 
Prazosin 8.3 7.4d 7.8 
Propranolol 8.0 7.7e 8.4 
Ranitidine 8.7 7.3e 7.7 
Ritonavir 11.6 8.6k 8.6 
a
threshold pX calculated from in silico values as in Table 4; 
b
threshold pX calculated from in vitro values 
using the same procedure as in Table 4 (CLintHH and fu values from ref [10], Papp values from [9] and [14] 
as specified, and in-house values for fuinc; 
c
threshold pX calculated from in vivo values [9] using the same 
procedure as in Table 4; 
d
Papp value from ref [9]; 
e
Papp value from ref [14]; 
f
fuinc value from in-house in 
silico model; 
g
no value (not enough experimental data available for calculation); 
h
in-house value for 
CLintHH; 
i
fu value from ref [17]; 
j






Most threshold pX values can be found within the range of 7-9, with a couple of values, especially in vivo 
derived, below 7 and others, most often in silico derived, above 9. Only one of the compounds for which 
human in vivo PK data was available showed an in vivo derived threshold pX values above 10, whereas all in 
vitro derived threshold pX values were actually below 10. The one compound with a higher in vivo data 
derived value, diclofenac, was earlier recognized as not being properly described by the one compartment 
PK model employed here [9]. For about a third of the compounds all three values are very close within 
about one log unit, e.g., carvedilol or nitrendipine. Other compounds have a somewhat higher spread, most 
often the in vitro value closer to the in vivo derived value, e.g., acebutolol or betaxolol. For a few 
compounds the in silico derived value is clearly differing from the other two, e.g., bisoprolol, diazepam and 
ritonavir. To better understand why we find the in silico predictions differ, we investigated how well the in 
silico and in vitro data can predict human in vivo properties (see Figures 2-4). Note that cyclosporine and 
desloratidine were excluded from this analysis, since there was not enough in vitro data for the former and 
no in vivo data for the latter compound.  
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Figure 1. Comparison of threshold pX values calculated from purely in silico (open circles), in vitro (black circles) 
or in vivo (black triangles) data as described in text.  
Figure 2 shows that in silico data tends to overpredict human clearance. The two compounds on the left, 
diazepam and ritonavir, are obvious extremes, and their higher estimate of the threshold potency value are 
most likely related to the clearance misprediction. Note that clearance predictions from in vitro are clearly 
closer to the line of unity. However, we find two compounds, diclofenac and metoprolol, to be under 
predicted by more than 3-fold using the present scaling approach. This can also be seen in a more 
optimistic threshold pX value when compared to in vivo (see Figure 1). Overall, about two thirds of the 
compounds have in silico predicted clearance values within 3-fold from the experimental in vivo values, and 
all but two compounds are within 3-fold utilizing in vitro values. 
 
Figure 2. Human in vivo plasma clearance plotted against predicted clearance based purely on in silico 
property calculations (open circles) and on in vitro data for human hepatocyte CLint, human protein binding 
and hepatocyte incubation binding (black circles). Full line indicates unity, dashed lines 3-fold limits. 
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Figure 3. Human in vivo plasma half-life plotted against predicted half-life based upon in silico volume of 
distribution and clearance calculated from in silico property calculations (open circles) or clearance calculated 
from in vitro data (black circles). Full line indicates unity, dashed lines 3-fold limits. 
Also the underprediction of half-life from in silico data is mostly due to the clearance prediction, while 
half-life prediction from in vitro, using the same in silico derived value for distribution volume, is clearly 
enhanced.  
Human fraction absorbed seems to be the most difficult parameter to predict correctly (see Figure 4). 
While both in silico and in vitro predictions identify the two compounds with Fabs below 0.4, compounds 
with Fabs between 0.4 and 0.6 were only recognized in two or three cases from in silico and in vitro data, 
respectively. However, this failure is not necessarily a concern in the present case, since the relationship 
between Fabs and plasma concentrations is assumed to be linear and a 2-fold change in fraction absorbed 
will lead to a 2-fold change in plasma concentration and thereby only to a 0.3 log units change for the 
threshold pX. Actually, Page [10] suggested, that estimation of Fabs as either 1 (acids) or 0.5 (all other ion 
classes) is sufficiently accurate for early D2M predictions. 
 
 
Figure 4. Human fraction absorbed plotted against predicted fraction absorbed from in silico Caco 
permeability prediction (black circles) or in vitro Caco permeability data (grey circles). Full line indicates unity, 
dashed lines 3-fold limits. 
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Influence of basic parameters – intrinsic clearance, fraction unbound in the hepatocyte incubation, plasma 
protein binding and volume of distribution 
Using pharmacokinetic equations assuming a one compartment model both dose and fraction absorbed 
are linearly related to the derived plasma concentrations and it is easily understood how either of these 
parameters will influence the threshold pIC50 calculation. The remaining four input parameters, CLintHH, 
fuinc, fu, and V, on the other hand are more intricately interlinked, especially since the first three also are 
included in the scaling approach converting in vitro (in silico) CLint to in vivo clearance using the well-stirred 
liver model (equations 5 and 9). In order to better understand how these parameters influence the 
outcome, threshold pIC50 values for hypothetical compounds with hepatocyte CLint values varying from 1 
to 200 l/min/106 cells, values for fraction unbound in the incubation varying from 0.01 to 0.7, values for 
protein binding (fu) varying from 0.001 to 0.3, and volume of distribution varying from 0.2 to 3 L/kg were 
calculated (see Figure 5). 
As expected, lower intrinsic clearance as measured in hepatocytes leads to a lower threshold pIC50 
estimate. However, the sensitivity of this correlation varies both with the fuinc/fub ratio and the volume of 
distribution: lower volume of distribution leads to higher sensitivity towards intrinsic clearance. 
Additionally, higher fuinc/fub ratios lead to lower sensitivity of the intrinsic clearance as well as of volume of 
distribution (see Figure 5, panel in upper right corner). Lower V leads to higher threshold pIC50 values and 
higher fuinc/fub ratios essentially lead to lower threshold pIC50s, at least as long as potency in blood assays, 
i.e., defined from total concentrations, is considered. The threshold pIC50 shifts up by three log units in the 
uppermost panel row (fu = 0.001) when free plasma concentrations are taken into account, whereas the 
threshold pIC50 in the lower panel row (fu = 0.3) shifts only by about 0.5 log units. 
Sensitivity analysis 
Sensitivity analysis is a useful tool for determining which parameters are important. Global sensitivity 
analysis is used to explore the entire parameter space, considering physiologically relevant values to 
determine the relative importance of each of them. Here it was shown that volume of distribution is the 
most influential parameter by far (see Figure 6).  
Local sensitivity analysis, on the other hand, can define how sensitive the calculation is to a parameter, 
when another parameter is scanned over its defined range. Here, we checked the influence of the 
remaining parameters for different values of volume of distribution (see Figure 7). CLintHH and fu have 
overlapping influence, considering a 10 % change, whereas fuinc is exacty opposite. Since in vivo CLint is 
multiplied by fu, when calculating Clb using the well stirred model (Eq. 5) and is calculated from CLintHH 
divided by fuinc (eqs 9 and 9a) this is not really surprising. Note that the influence of the parameters is 
highest at low volume of distribution values, decreases quickly and does not change further as soon as V 
reaches a value of 2 L/kg. Considering typical volume ranges for acids, bases and neutrals with median 
values of 0.2 L/kg, 2.9 L/kg and 1.3 L/kg, respectively [10, 17], as indicated in Figure 7, it is clear that 
especially for acids a small change in either hepatocyte CLint or binding properties can make a big 
difference for the prediction of threshold pIC50 determined from Cmin.  
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Figure 5. Threshold pIC50 estimated from minimum plasma concentration for hypothetical compounds as 
calculated from human hepatocyte CLint values (1-200 µl/min/10
6
 cells, x-axis), fraction unbound in the 
incubation (fuinc = 0.01 – 0.7; panel columns), fraction unbound in blood (fub = 0.001 – 0.3; panel rows), and 
volume of distribution (V = 3 L/kg, black, V = 2 L/kg, dark grey, V = 1 L/kg, medium grey, V = 0.4 L/kg, light 
grey, V = 0.2 L/kg, very light grey). Values in the corner of each panel indicate the fuinc/fub ratio. Lower left 
panels left empty since compounds are usually less bound in the hepatocyte incubation than in plasma. 
 
 
Figure 6. Global sensitivity towards the four parameters to determine threshold pIC50. 
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Figure 7. Sensitivity of remaining three parameters for different V values (CLintHH and fu full line, fuinc dashed 
line; CLint and fu have exactly same influence and are on top of each other, fuinc has opposite effect), areas of 
typical distribution volume values for acids, bases and neutrals indicated. 
Influence of in silico model quality 
The quality of the in silico models needs to be considered for the present analysis. Here we use 
AstraZeneca’s in-house models for the five parameters, two of which have rather extensive training sets 
with more than 10,000 data points each, gathered over a long period of time (>10 years), whereas two, fuinc 
and Papp, have intermediate training set size, and the fifth, volume of distribution, is based on literature 
data and uses only about 500 compounds. For the four models employing in-house data, about 70-75 % of 
the compounds within a temporal test set, i.e., compounds that have not been available when the model 
was built, were found to be within 3-fold of the experimental value. These results are rather encouraging 
when considering that the experimental variability in general is assumed to be about 2-fold [38]. The 
models are being regularly updated, as it was shown earlier that continuous updates of models enables 
new chemistry to be well represented and, thus, likely better predicted by the models [39]. It should be 
emphasized that the predictivity of the models needs to be investigated for the drug discovery project or 
chemical series in question when this approach is to be applied. Note that, as was shown in Figure 2, 
clearance prediction are reasonably accurate from in silico for most compounds in data set 2 and can be 
directly verified as soon as in vitro data is available for a compound.  
The remaining parameter, human distribution volume, is less easily available. The QSAR model used 
here is based on human literature data and cannot be updated as straightforwardly as models using data 
from in-house screens. Also, external data is not necessarily relevant to newest in-house chemistry, and 
model outcome can usually only be verified at later stages since in vivo data is required. Nevertheless, the 
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predictivity was considered good, with an error of prediction to be 0.4 log units (2.5-fold), and scrutinizing 
literature or databases for new data [40-42] in fairly regular intervals should ensure continued high quality 
of the model. 
Conclusions 
The present study suggests the usage of in silico ADME predictions to estimate which plasma 
concentration a new chemical structure may achieve when given orally using a defined dose and dosing 
regimen. From the plasma concentration a minimum required potency can be deduced, here referred to as 
threshold potency (or threshold pIC50). While it was postulated, that early dose predictions from in silico 
was not yet possible [10], the idea here is to utilise predictions only to consider a compound’s summarized 
pharmacokinetic properties for ranking compounds within a series early on in the design process. 
Combining the in silico predictions to a physiologically meaningful score, reduces the risk of deselecting a 
compound just because one of the parameters is outside an arbitrarily chosen limit.  
Using the approach for a set of drug discovery compounds, it was shown that the threshold pIC50 was 
able to define which compounds had a higher or lower chance of success, with the finally selected 
compound in the former set. It was assumed that the approach is most useful in lead optimisation stage, 
when the requirements for potency coverage are known. 
 Additionally, it was shown that the threshold potency values calculated for a set of marketed drugs 
were in a reasonable range for most of the compounds, when appropriate dosing regimens were 
considered for each. These results were also compared with the outcome, when experimental in vitro or 
human in vivo data were considered as input for the same procedure. In silico outcome was in many cases 
similar to both in vitro and in vivo, and when there were bigger differences usually the in vitro was closer to 
the in vivo outcome. Thus, in silico prediction can be easily verified by in vitro experiments as soon as a 
compound is made.  
The examples shown here based threshold potency values on oral dosing and minimum concentration, 
i.e., required coverage over the whole dosing period. Using such a dosing regimen, and based on a one 
compartment pharmacokinetic model considering immediate absorption, volume of distribution becomes 
the most important factor. Special care needs to be taken for low volume compounds such as acids. 
Obviously, the equations can be adapted to other coverage periods or dosing regimen, as required by the 
specific drug discovery project. 
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